JP Morgan Chase Portfolio holdings
JPMorgan Chase & Co., formed by the 2000 merger of J.P. Morgan & Co. and Chase Manhattan Bank, is a global financial services giant headquartered in New York City, tracing its roots back to 1799 through its predecessor firms. As one of the largest banks in the world, it operates across investment banking, commercial banking, asset management, and consumer banking, managing trillions in assets and serving millions of customers, corporations, and governments. Led by CEO Jamie Dimon since 2005, the firm is renowned for its role in high-profile deals, robust trading operations, and its Chase retail banking network, which includes extensive credit card and mortgage services. Combining a legacy of financial innovation with a dominant market presence, JPMorgan Chase remains a cornerstone of the global economy.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vanguard Intermediate-Term Corporate Bond ETF
VCIT
|
+$3.46B |
| 2 |
Microsoft
MSFT
|
+$2.83B |
| 3 |
Eli Lilly
LLY
|
+$2.1B |
| 4 |
Broadcom
AVGO
|
+$1.33B |
| 5 |
Stryker
SYK
|
+$1.24B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vanguard S&P 500 ETF
VOO
|
+$3.18B |
| 2 |
iShares Core S&P 500 ETF
IVV
|
+$2.39B |
| 3 |
iShares Core S&P Mid-Cap ETF
IJH
|
+$2.35B |
| 4 |
Alphabet (Google) Class C
GOOG
|
+$2.07B |
| 5 |
iShares 7-10 Year Treasury Bond ETF
IEF
|
+$1.5B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 26.04% |
| 2 | Technology | 20.48% |
| 3 | Healthcare | 9.65% |
| 4 | Financials | 9.27% |
| 5 | Consumer Discretionary | 8.86% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
5801
HUTCHMED
HCM
$2.53B
| $42.3K | ﹤0.01% |
2,337
+3
| +0.1% | +$55 |
2017 Q2
26 quarters
|
|
|
FAX
5802
abrdn Asia-Pacific Income Fund
FAX
$530M
| $41.8K | ﹤0.01% |
+2,573
| New | +$40K |
2023 Q4
0 quarters
|
|
|
CIFRW
5803
DELISTED
Cipher Mining Warrant
CIFRW
| – | – |
0
| – | – |
2023 Q2
2 quarters
|
|
5804
Mach Natural Resources
MNR
$1.72B
| $41.7K | ﹤0.01% |
+2,530
| New | +$43.8K |
2023 Q4
0 quarters
|
|
5805
Eaton Vance Tax-Managed Diversified Equity Income Fund
ETY
$2.24B
| $41.4K | ﹤0.01% |
3,396
+580
| +21% | +$6.71K |
2022 Q4
4 quarters
|
|
5806
FinWise Bancorp
FINW
$155M
| $41.3K | ﹤0.01% |
+2,889
| New | +$30.8K |
2023 Q4
0 quarters
|
|
5807
WisdomTree Voya Yield Enhanced USD Universal Bond Fund
UNIY
$1.26B
| $41.2K | ﹤0.01% |
+832
| New | +$39.5K |
2023 Q4
0 quarters
|
|
5808
Nuvectis Pharma
NVCT
$676M
| $40.9K | ﹤0.01% |
4,902
| – | – |
2023 Q2
2 quarters
|
|
|
MUE
5809
DELISTED
BlackRock MuniHoldings Quality Fund II
MUE
| $40.8K | ﹤0.01% |
+4,069
| New | +$38.1K |
2023 Q4
0 quarters
|
|
|
AVK
5810
Advent Convertible and Income Fund
AVK
$500M
| $40.8K | ﹤0.01% |
3,678
+3,267
| +795% | +$32.8K |
2022 Q4
4 quarters
|
|
|
ANSCU
5811
DELISTED
Agriculture & Natural Solutions Acquisition Corp Unit
ANSCU
| $40.6K | ﹤0.01% |
+4,000
| New | +$40.4K |
2023 Q4
0 quarters
|
|
5812
Ellomay Capital Ltd
ELLO
$309M
| $40.1K | ﹤0.01% |
+2,682
| New | +$34.7K |
2023 Q4
0 quarters
|
|
5813
Prelude Therapeutics
PRLD
$302M
| $40.1K | ﹤0.01% |
9,380
-7,973
| -46% | -$24.3K |
2020 Q4
12 quarters
|
|
5814
NN Inc
NNBR
$300M
| $39.9K | ﹤0.01% |
9,982
+9,815
| +5,877% | +$23.3K |
2013 Q2
42 quarters
|
|
5815
Playboy Inc
PLBY
$121M
| $39.9K | ﹤0.01% |
39,882
| – | – |
2021 Q2
10 quarters
|
|
|
GAN
5816
DELISTED
GAN Ltd
GAN
| $39.8K | ﹤0.01% |
25,193
+24,693
| +4,939% | +$32.9K |
2020 Q2
14 quarters
|
|
5817
Outlook Therapeutics
OTLK
$140M
| $39.7K | ﹤0.01% |
5,039
| – | – |
2021 Q2
10 quarters
|
|
|
BLCN
5818
DELISTED
Siren ETF Trust Siren NexGen Economy ETF
BLCN
| $39.6K | ﹤0.01% |
1,620
-38
| -2% | -$785 |
2022 Q3
5 quarters
|
|
|
PHD
5819
DELISTED
Pioneer Floating Rate Fund
PHD
| $39.4K | ﹤0.01% |
+4,294
| New | +$38.5K |
2023 Q4
0 quarters
|
|
5820
INmune Bio
INMB
$53.6M
| $39.2K | ﹤0.01% |
+3,479
| New | +$29.2K |
2023 Q4
0 quarters
|
|
5821
Invesco RAFI Strategic US ETF
IUS
$962M
| $39K | ﹤0.01% |
900
-4,000
| -82% | -$163K |
2023 Q2
2 quarters
|
|
5822
CALL
Corebridge Financial
CRBG
$15B
| $39K | ﹤0.01% |
+1,800
| New | +$37.1K |
2023 Q4
0 quarters
|
|
5823
C4 Therapeutics
CCCC
$386M
| $38.9K | ﹤0.01% |
6,893
-2,242
| -25% | -$5.11K |
2020 Q4
12 quarters
|
|
|
ZJYL
5824
Jin Medical International
ZJYL
$147M
| $38.9K | ﹤0.01% |
157
-116
| -42% | -$3.93K |
2023 Q3
1 quarter
|
|
5825
Stereotaxis
STXS
$120M
| $38.8K | ﹤0.01% |
22,154
+22,042
| +19,680% | +$35.6K |
2020 Q2
14 quarters
|
|
Similar funds
JP Morgan Chase's Q4 2023 Portfolio in Review
As of Q4 2023, JP Morgan Chase held 8,129 positions worth $1.04T, up 15% from $906B the previous quarter. Its ten largest holdings account for 20% of the portfolio.
JP Morgan Chase's Q4 2023 filing shows 701 new, 3,661 increased, 2,247 reduced and 617 closed positions. Its largest new stake was JPMorgan US Tech Leaders ETF: 3,149,069 shares worth $185M. The largest sale was Vanguard S&P 500 ETF, an estimated $3.18B.
By sector, the portfolio is most concentrated in Miscellaneous at 26% of assets, down from 26% a quarter earlier, followed by Technology and Healthcare.
- JP Morgan Chase's largest Q4 2023 buy was JPMorgan US Tech Leaders ETF: 3,149,069 shares worth $185M.
- JP Morgan Chase added most to Vanguard Intermediate-Term Corporate Bond ETF in Q4 2023, an estimated $3.46B increase.
- JP Morgan Chase's biggest Q4 2023 reduction was Vanguard S&P 500 ETF, cutting an estimated $3.18B.
- JP Morgan Chase fully exited Activision Blizzard in Q4 2023, selling an estimated $1.06B.
- JP Morgan Chase's ten largest holdings make up 20% of its $1.04T portfolio in Q4 2023.
- JP Morgan Chase opened 701 new positions and closed 617 in Q4 2023.
- JP Morgan Chase's portfolio value rose 15% quarter-over-quarter to $1.04T.
Based on JP Morgan Chase's 13F filing for Q4 2023, filed 12 Feb 2024.